温馨提示：本站仅提供公开网络链接索引服务，不存储、不篡改任何第三方内容，所有内容版权归原作者所有
AI智能索引来源：http://www.ft.com/pharmaceuticals
点击访问原文链接

Pharmaceuticals sector | Financial Times

进入原网站 导航首页
Accessibility helpSign InSubscribeFinancial TimesSubscribeSign InHomeWorldWorld HomeMiddle East warGlobal EconomyUKUSChinaAfricaAsia PacificEmerging MarketsEuropeWar in UkraineAmericasMiddle East & North AfricaKharg Island: Iran’s oil lifeline that Trump has left untouchedTrump’s Venezuela strategy has failed in IranWhich economies will pay the biggest price for the Iran war?Farage misses out on Trump meeting as their relationship coolsG7 discuss joint release of emergency oil reservesUSUS HomeUS EconomyUS CompaniesUS Politics & PolicyKharg Island: Iran’s oil lifeline that Trump has left untouchedTrump’s Venezuela strategy has failed in IranWhich economies will pay the biggest price for the Iran war?Farage misses out on Trump meeting as their relationship coolsIran war will leave a complex geoeconomic legacyCompaniesCompanies HomeEnergyFinancialsHealthIndustrialsMediaProfessional ServicesRetail & ConsumerTech SectorTelecomsTransportKharg Island: Iran’s oil lifeline that Trump has left untouchedWhich economies will pay the biggest price for the Iran war?G7 discuss joint release of emergency oil reservesEx-EY executive launches private equity-backed tax firm to challenge Big FourPimco sticks with bet on gilts despite market slumpTechTech HomeArtificial intelligenceSemiconductorsCyber SecuritySocial MediaSheryl Sandberg and Nick Clegg join Nvidia-backed AI start-up NscaleAnthropic sues the Pentagon over being declared a ‘supply chain risk’KKR eyes multibillion-dollar sale of data centre cooling companyMicrosoft adds Anthropic AI models to its Copilot workplace toolsIs South Korea’s dominant online retailer an American company?MarketsMarkets HomeAlphavilleMarkets DataCryptoCapital MarketsCommoditiesCurrenciesEquitiesMonetary Policy RadarWealth ManagementMoral MoneyETF HubFund ManagementTradingKharg Island: Iran’s oil lifeline that Trump has left untouchedWhich economies will pay the biggest price for the Iran war?G7 discuss joint release of emergency oil reservesIran war will leave a complex geoeconomic legacyPimco sticks with bet on gilts despite market slumpClimateOpinionOpinion HomeColumnistsThe FT ViewThe Big ReadLexObituariesLettersTrump’s Venezuela strategy has failed in IranIran war will leave a complex geoeconomic legacyAmerica chose this war — and must now choose how to end itStagflationary forces are buildingWhy it’s time to end the grim march of the touchscreenLexWork & CareersWork & Careers HomeBusiness School RankingsBusiness EducationEurope's Start-Up HubsEntrepreneurshipRecruitmentBusiness BooksBusiness TravelWorking ItWhy it’s time to end the grim march of the touchscreenYou can turn this to your advantage if every news story has ‘tax exile’ in itBusiness school professors’ picksLife & ArtsLife & Arts HomeArtsBooksFood & DrinkFT MagazineHouse & HomeStylePuzzlesTravelFT GlobetrotterHow to wear a tie: HTSI’s definitive guideWine storage is emerging from the cellarThe new food fad sweeping KoreaFlip it and reverse it: the enduring fun of Jaeger-LeCoultre’s Reverso ‘Match of the century’ referee Lothar Schmid’s chess library up for auctionHow To Spend ItCompaniesHealthPharmaceuticalsHomeWorldUSCompaniesTechMarketsClimateOpinionLexWork & CareersLife & ArtsHow To Spend ItFinancial TimesSubscribeSign InHims & Hers Health IncHims shares shoot up after weight-loss drug deal with Novo NordiskUS telehealth group and Danish drugmaker have been in dispute over copycat medicinesZealand Pharma ASBiotech group’s shares hit by weight-loss drug setbackZealand Pharma falls 34% following mid-stage trial results for treatment being developed with RocheDrug pricesTrump’s ambassador to UK rebukes head of medicines watchdog over drug pricingWarren Stephens calls in Nice chief to express displeasure at Jonathan Benger’s defence of Britain’s cost-control systemLife & ArtsFT Magazine. A year on a cancer vaccine trial at London’s oldest hospitalThis 21st-century centre of cutting-edge science is also a medieval site of celestial auguries, of miracle cures performed and witnessedDrugs researchLongevity and ‘wellness’ craze breaks untested drugs out of the labHealth influencers promise an astonishing range of benefits from peptides, almost none of them tested in humansDisease control and preventionNew single-pill HIV therapy promises boost for long-term virus survivorsSolo tablet worked well for patients who were older and in many cases resistant to existing treatmentsUK companiesGSK secures potential ‘multi-blockbuster’ drug in $950mn dealNew chief Luke Miels swoops on Canada’s 35Pharma in push to replenish pipeline and boost revenuesScienceNovo Nordisk Foundation backs quantum computing and life sciences beyond DenmarkWorld’s richest philanthropic organisation is co-ordinating with EU about research and innovation strategyMergers & AcquisitionsLex. Why 2026 will be a blockbuster year for biotech M&ABig pharma has emerged from its 2025 paralysis with plenty of firepowerDrug pricesNovo Nordisk halves US price of weight-loss drugDanish group is struggling to compete with rival Eli Lilly in the obesity marketUS-UK relationsUK PR executive left role after US embassy raised concerns over online postsGavin Megaw’s exit from Hanover followed complaint by embassy to American Pharmaceutical GroupNovo Nordisk ASNovo Nordisk shares drop 16% after poor trial results for new obesity drugOnce-a-week injection achieved less weight loss than rival treatmentBiotechMerck splits operations to separate oncology from non-cancer drugsReshuffle in preparation for 2028 US patent expiry of blockbuster cancer treatment KeytrudaGilead Sciences IncGilead to buy cancer drug developer Arcellx for up to $7.8bnDeal comes as pharmaceutical groups rush to acquire smaller biotechs with proven drug pipelinesGenomicsCats give genetic clues to better cancer treatmentsSimilarities between pet and human tumours suggest new ideas for targeting bothDisease control and preventionTrump administration reverses move to block Moderna flu vaccine trialU-turn comes after backlash from the company and US biotech industryScienceBrain drain is undermining America’s scientific edgePolicy decisions grounded in Maga talking points are helping to fuel a PhD exodus from governmentAnjana AhujaBayer AGBayer aims to settle Roundup claims over alleged cancer links for $7.25bnGerman group warned alternative to settlement was ‘spending decades in legal disputes’BiotechDanaher strikes $10bn deal for medical device maker MasimoAcquisition by US life sciences manufacturer makes it a market leader in production of pulse oximetersHims & Hers Health IncLex. Hims & Hers is a brave bet on solving disrupter’s dilemmaPlan to make longevity affordable means muscling in on territory occupied by drugs giants and pharmaciesSanofi SASanofi replaces chief with Merck executive after R&D woesFrench drugmaker says incoming boss Belén Garijo will bring ‘increased rigour’AstraZeneca PLCLex. How AstraZeneca shot for the moon — and hitGetting one’s laboratories to do the hard work is a durable recipe for successAstraZeneca PLCChina charges former AstraZeneca executiveLeon Wang, who has been in detention since 2024, is charged alongside another ex-employee of drugmakerMedical scienceThe shingles vaccine may have a dementia upsideResearch suggests it could prevent and slow the progress of cognitive declineAnjana AhujaEuropean companiesStrong cancer drug sales boost AstraZeneca earningsUK drugmaker reports 16 positive late-stage trial results for 2025Join us at an FT Live eventFT LiveCapital, Competition and the Patent CliffFT LiveUS Pharma and Biotech SummitFT LiveGlobal Pharma and Biotech SummitExplore all eventsHelp CentreContact UsAbout UsAccessibilityCareersSuppliersTerms & ConditionsPrivacy PolicyCookie PolicyManage CookiesCopyrightSlavery Statement & PoliciesShare News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT SchoolsPortfolioFT AppFT Digital EditionFT EditAlerts HubBusiness School RankingsSubscription ManagerNews feedNewslettersCurrency ConverterFT Live EventsFT ForumsFT Leaders AcademyMore from the FT GroupFT Editorial Code of PracticeUKSubscribe for full accessHomeWorldMiddle East warGlobal EconomyUKUSChinaAfricaAsia PacificEmerging MarketsEuropeWar in UkraineAmericasMiddle East & North AfricaUSUS EconomyUS CompaniesUS Politics & PolicyCompaniesEnergyFinancialsHealthIndustrialsMediaProfessional ServicesRetail & ConsumerTech SectorTelecomsTransportTechArtificial intelligenceSemiconductorsCyber SecuritySocial MediaMarketsAlphavilleMarkets DataCryptoCapital MarketsCommoditiesCurrenciesEquitiesMonetary Policy RadarWealth ManagementMoral MoneyETF HubFund ManagementTradingClimateOpinionColumnistsThe FT ViewThe Big ReadLexObituariesLettersLexWork & CareersBusiness School RankingsBusiness EducationEurope's Start-Up HubsEntrepreneurshipRecruitmentBusiness BooksBusiness TravelWorking ItLife & ArtsArtsBooksFood & DrinkFT MagazineHouse & HomeStylePuzzlesTravelFT GlobetrotterPersonal FinanceProperty & MortgagesInvestmentsPensionsTaxBanking & SavingsAdvice & CommentHow To Spend ItSpecial ReportsAlphavilleFT EditLunch with the FTFT Globetrotter#techAsiaMoral MoneyVisual and data journalismNewslettersVideoPodcastsNews feedFT SchoolsFT Live EventsFT ForumsFT Leaders AcademymyFTPortfolioFT Digital EditionCrosswordOur AppsHelp CentreSubscribeSign In

智能索引记录